share_log

Illumina | 8-K: Current report

Illumina | 8-K: Current report

Illumina | 8-K:重大事件
美股SEC公告 ·  05/20 16:12

Moomoo AI 已提取核心信息

Illumina, Inc., a biotechnology company, held its 2024 annual meeting of stockholders on May 16, 2024. During the meeting, stockholders voted on several key proposals. The first proposal, which was approved, involved the election of Frances Arnold, Caroline Dorsa, Robert Epstein, Scott Gottlieb, Gary Guthart, Stephen MacMillan, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen, and Scott Ullem to the Board of Directors for a one-year term. The second proposal, also approved, ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 29, 2024. The third proposal, which received advisory approval, was regarding the compensation paid to the company's named executive officers. The detailed voting results for each proposal were disclosed, with the majority of votes cast in favor of the proposed actions. The report was signed by Charles E. Dadswell, General Counsel and Secretary of Illumina, Inc., on May 20, 2024.
Illumina, Inc., a biotechnology company, held its 2024 annual meeting of stockholders on May 16, 2024. During the meeting, stockholders voted on several key proposals. The first proposal, which was approved, involved the election of Frances Arnold, Caroline Dorsa, Robert Epstein, Scott Gottlieb, Gary Guthart, Stephen MacMillan, Anna Richo, Philip Schiller, Susan Siegel, Jacob Thaysen, and Scott Ullem to the Board of Directors for a one-year term. The second proposal, also approved, ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 29, 2024. The third proposal, which received advisory approval, was regarding the compensation paid to the company's named executive officers. The detailed voting results for each proposal were disclosed, with the majority of votes cast in favor of the proposed actions. The report was signed by Charles E. Dadswell, General Counsel and Secretary of Illumina, Inc., on May 20, 2024.
生物技术公司Illumina, Inc. 于2024年5月16日举行了2024年年度股东大会。会议期间,股东对几项关键提案进行了投票。第一项提案获得批准,涉及弗朗西斯·阿诺德、卡罗琳·多尔萨、罗伯特·爱泼斯坦、斯科特·戈特利布、加里·古塔特、斯蒂芬·麦克米兰、安娜·里乔、菲利普·席勒、苏珊·西格尔、雅各布·塞森和斯科特·乌勒姆当选为董事会成员,任期一年。第二项提案也获得批准,批准任命安永会计师事务所为公司截至2024年12月29日的财政年度的独立注册会计师事务所。第三项提案已获得咨询批准,涉及向公司指定执行官支付的薪酬。每项提案的详细投票结果均已披露,多数票赞成拟议的行动。该报告由Illumina, Inc.总法律顾问兼秘书查尔斯·达德斯韦尔于2024年5月20日签署。
生物技术公司Illumina, Inc. 于2024年5月16日举行了2024年年度股东大会。会议期间,股东对几项关键提案进行了投票。第一项提案获得批准,涉及弗朗西斯·阿诺德、卡罗琳·多尔萨、罗伯特·爱泼斯坦、斯科特·戈特利布、加里·古塔特、斯蒂芬·麦克米兰、安娜·里乔、菲利普·席勒、苏珊·西格尔、雅各布·塞森和斯科特·乌勒姆当选为董事会成员,任期一年。第二项提案也获得批准,批准任命安永会计师事务所为公司截至2024年12月29日的财政年度的独立注册会计师事务所。第三项提案已获得咨询批准,涉及向公司指定执行官支付的薪酬。每项提案的详细投票结果均已披露,多数票赞成拟议的行动。该报告由Illumina, Inc.总法律顾问兼秘书查尔斯·达德斯韦尔于2024年5月20日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息